Bicara Therapeutics Inc. Common Stock (BCAX)
Stock · NASDAQ · Health Care
$16.78as of 10/16/2026
Price chart
Active signals
BCAX Signal Track Record
How signals performed across all stocks →What BCAX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 7 | +5.0% | 71% | September 23, 2026 |
| Volume Spike | 7 | +1.4% | 57% | September 18, 2026 |
| Bollinger Band Breakout | 5 | +5.3% | 100% | June 17, 2026 |
| Any 20-session window (baseline) | +1.6% | 53% |
Computed by MarketWall from daily closing prices since July 2, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 103
- Website
- www.bicara.com/
Fundamentals
- 1-day range
- $17.01$17.61
- Market cap
- $1.81B
- P/E (trailing)
- —
- P/E (forward)
- -4.93
- EPS (trailing)
- $-3.09
- Dividend yield
- —
- Beta
- 0.73
- Avg. volume
- 628.0K
Forecasts
12 analyst ratings
Bicara Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
- CMPSCOMPASS Pathways Plc American Depository Shares$10.75▼ 7.49%Market cap $1.83BP/E —$4.88$15.87
- NBTXNanobiotix S.A. American Depositary Shares$21.3▼ 4.18%Market cap $1.83BP/E —$13.1$47.66
- KARDKardigan Inc. Common Stock$13.03▼ 6.12%Market cap $1.79BP/E —$12.23$27
- SEPNSepterna Inc. Common Stock$36.35▼ 2.94%Market cap $1.78BP/E —$17.55$51.1
- GENBGenerate Biomedicines Inc. Common Stock$12.09▼ 7.43%Market cap $1.78BP/E —$11$22.67
- DMRADamora Therapeutics Inc. Ordinary Shares$18.44▼ 1.60%Market cap $1.84BP/E —$16.5$34.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
| CMPS COMPASS Pathways Plc American Depository Shares | $1.83B | — | $10.75 | ▼ 7.49% | $4.88$15.87 |
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $21.3 | ▼ 4.18% | $13.1$47.66 |
| KARD Kardigan Inc. Common Stock | $1.79B | — | $13.03 | ▼ 6.12% | $12.23$27 |
| SEPN Septerna Inc. Common Stock | $1.78B | — | $36.35 | ▼ 2.94% | $17.55$51.1 |
| GENB Generate Biomedicines Inc. Common Stock | $1.78B | — | $12.09 | ▼ 7.43% | $11$22.67 |
| DMRA Damora Therapeutics Inc. Ordinary Shares | $1.84B | — | $18.44 | ▼ 1.60% | $16.5$34.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Ryan Cohlhepp · September 8, 2026 · Option Exercise17.5K @ $3.79
- Ryan Cohlhepp · September 8, 2026 · Sale3.4K @ $23.43
- Ryan Cohlhepp · September 8, 2026 · Sale14.1K @ $22.77
- Larson Jennifer · August 12, 2026 · Grant285.0K
- Claire Mazumdar · August 10, 2026 · Sale10.0K @ $27.98
- Ryan Cohlhepp · August 10, 2026 · Option Exercise18.8K @ $3.79
- Ryan Cohlhepp · August 10, 2026 · Sale18.8K @ $27.98
- Ivan Hyep · August 10, 2026 · Option Exercise12.5K @ $3.79
- Ivan Hyep · August 10, 2026 · Sale12.5K @ $27.97
- Claire Mazumdar · August 10, 2026 · Option Exercise10.0K @ $3.79
- Jeremy Bender · July 28, 2026 · Grant39.0K
- Oliger Christy J. · July 28, 2026 · Grant39.0K
- Claire Mazumdar · July 10, 2026 · Option Exercise10.0K @ $3.79
- Claire Mazumdar · July 10, 2026 · Sale28 @ $29.68
- Claire Mazumdar · July 10, 2026 · Sale10.0K @ $28.42
Institutional Ownership
March 31, 2026
- Total shares held
- 70.78M
- Total value held
- $1.22B
- Institutional holders
- 142
- Unknown7.26M
- Unknown6.61M
- Unknown5.80M
- Unknown5.42M
- Unknown4.06M
- Unknown3.34M
- Unknown3.17M
- Unknown3.01M
- Unknown2.84M
- Unknown2.39M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BCAX flagged as potentially overvalued on book value
A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.
BCAX flagged as potentially overvalued on book value. A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.